Search Result

Results for "

CBP Bromodomain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) CTLA-4 (1) Deubiquitinase (1) Epigenetic Reader Domain (36) Histone Acetyltransferase (11) LAG-3 (1) Ligands for Target Protein for PROTAC (3) MDM-2/p53 (2) PD-1/PD-L1 (1) PROTACs (3) Reference Standards (2)
By Research Areas:	Cancer (35) Cardiovascular Disease (2) Inflammation/Immunology (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111784

Inobrodib 10+ Cited Publications CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .

HY-15826

SGC-CBP30 Maximum Cited Publications 20 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective **CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300*, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain* of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-136938

NEO2734 4 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-19541

I-CBP112 5 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112, a chemical probe, is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent *CBP/EP300* bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for *CBP, EP300* and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for *CBP* .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-120028

GNE-207	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of *CBP, with an IC₅₀* of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an EC₅₀ of 18 nM for MYC expression in MV-4-11 cells .

HY-101125

L-Moses 2 Publications Verification L-45	Epigenetic Reader Domain	Cancer
L-Moses (L-45), a chemical probe, is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-147868

DC-CPin711	Epigenetic Reader Domain Apoptosis	Cancer
DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the **CBP/P300 family of bromodomains*. CBP/p300-IN-8 inhibits CBP* (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-110315

Ischemin sodium	Apoptosis MDM-2/p53 Epigenetic Reader Domain	Cardiovascular Disease
Ischemin sodium is a *CBP* bromodomain inhibitor that inhibits p53 interaction with *CBP* and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC₅₀ value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .

HY-100697

TPOP146 3 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
TPOP146 is a selective *CBP/P300* benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.

HY-164005

CBP/EP300 bromodomain receptor-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-19541A

I-CBP112 hydrochloride	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of *CBP/P300* that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .

HY-110315A

Ischemin	Epigenetic Reader Domain Apoptosis MDM-2/p53	Cardiovascular Disease
Ischemin is a *CBP* bromodomain inhibitor that inhibits p53 interaction with *CBP* and transcriptional activity in cells. Ischemin inhibits p53-induced p21 activation with an IC₅₀ value of 5 µM. Ischemin also prevents apoptosis in ischemic cardiomyocytes. Ischemin can be used in the study of cardiovascular diseases (such as myocardial ischemia) .

HY-101125A

L-Moses dihydrochloride 2 Publications Verification L-45 dihydrochloride	Epigenetic Reader Domain	Cancer
L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-157134

Y08262	Epigenetic Reader Domain	Cancer
Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC₅₀ value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .

HY-161958

dCE-2	PROTACs Histone Acetyltransferase	Cancer
dCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) ^{[1] ^.}

HY-142743

Y08175	Epigenetic Reader Domain	Cancer
Y08175 is a potent **CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC₅₀*s of 37 and 178.15 nM against CBP* bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active **CBP bromodomain** inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .

HY-147869

DC-CPin7	Epigenetic Reader Domain	Cancer
DC-CPin7 is a potent inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 2.5 μM .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-168464

Y16526	Epigenetic Reader Domain	Cancer
Y16526 is a potent inhibitor of **CBP/p300 bromodomain , with the IC₅₀** of 0.03 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML) .

HY-161960

EP300/CBP ligand 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-123758

XDM-CBP	Epigenetic Reader Domain	Cancer
XDM-CBP is a CBP/p300 inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .

HY-149806

Bromodomain IN-2	Epigenetic Reader Domain	Cancer
BD-IN-1 is a pan bromodomain (BD) inhibitor with K_D values of 250, 420, 130, 430, 67, 240, 970 nM for BRD4(1), CBP, BRPF1B, BRD7, BRD9, BRDT(1), CECR2 respectively. BD-IN-1 shows antiproliferative activity .

HY-101125B

D-Moses D-45	Epigenetic Reader Domain	Cancer
D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .

HY-W173361

CBP/p300-IN-24	Epigenetic Reader Domain	Others
CBP/p300-IN-24 (compound 1) is a *CBP* bromodomain inhibitor with an IC₅₀ of 32 μM and selectivity over BRD4 BD-1 bromodomain.CBP/p300-IN-24 binds to the acetyl lysine binding pocket, forms hydrogen bonds with Asn1168 and a solvent-mediated hydrogen bond with Tyr1125, and forms hydrophobic interactions with Leu1120, Ile1122, and Val1174 .

HY-122081

CPI-644	Histone Acetyltransferase LAG-3 CTLA-4 PD-1/PD-L1	Cancer
CPI-644 is a selective *EP300/CBP* bromodomain inhibitor, with an IC₅₀ of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 ⁺cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research .

HY-100697R

TPOP146 (Standard)	Epigenetic Reader Domain Reference Standards Histone Acetyltransferase	Cancer
TPOP146 (Standard) is the analytical standard of TPOP146 (HY-100697). This product is intended for research and analytical applications. TPOP146 is a selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4.

HY-168463

Y16524	Epigenetic Reader Domain	Cancer
Y16524 is a potent inhibitor of **CBP/p300 bromodomain , with the IC₅₀** of 0.01 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML) .

HY-100482R

CPI-637 (Standard)	Epigenetic Reader Domain Reference Standards Histone Acetyltransferase	Cancer
CPI-637 (Standard) is the analytical standard of CPI-637 (HY-100482). This product is intended for research and analytical applications. CPI-637 is a selective and potent CBP/EP300 bromodomain inhibitor with IC50 values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, EP300 and BRD4 BD-1, respectively, and an EC50 of 0.3 μM for CBP .

HY-180804

CZL-077	Epigenetic Reader Domain	Cancer
CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor (p300 IC₅₀ = 0.034 μM, *CBP* IC₅₀ = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins (BRD2/3/4). CZL-077 inhibits cell growth with IC₅₀ values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research .

HY-183817

GNE-781-COOH	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
GNE-781-COOH is a CBP/p300 degrader. GNE-781-COOH also acts as a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), which can be used to synthesize PROTAC CBP/P300 Degrader-4 (HY-183802) .

HY-183724

MS8572	Deubiquitinase	Inflammation/Immunology
MS8572 is a selective OTUB1 covalent ligand. MS8572 covalently modifies the noncatalytic cysteine 23 residue of OTUB1 and does not inhibit OTUB1 deubiquitinase activity. MS8572 can be used for development of deubiquitinase-targeting chimeras for targeted protein stabilization .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CBP Bromodomain

Inhibitors & Agonists